196 related articles for article (PubMed ID: 31060628)
1. Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells.
Zwergel C; Schnekenburger M; Sarno F; Battistelli C; Manara MC; Stazi G; Mazzone R; Fioravanti R; Gros C; Ausseil F; Florean C; Nebbioso A; Strippoli R; Ushijima T; Scotlandi K; Tripodi M; Arimondo PB; Altucci L; Diederich M; Mai A; Valente S
Clin Epigenetics; 2019 May; 11(1):68. PubMed ID: 31060628
[TBL] [Abstract][Full Text] [Related]
2. Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.
Valente S; Liu Y; Schnekenburger M; Zwergel C; Cosconati S; Gros C; Tardugno M; Labella D; Florean C; Minden S; Hashimoto H; Chang Y; Zhang X; Kirsch G; Novellino E; Arimondo PB; Miele E; Ferretti E; Gulino A; Diederich M; Cheng X; Mai A
J Med Chem; 2014 Feb; 57(3):701-13. PubMed ID: 24387159
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 4-amino-N- (4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation.
Rilova E; Erdmann A; Gros C; Masson V; Aussagues Y; Poughon-Cassabois V; Rajavelu A; Jeltsch A; Menon Y; Novosad N; Gregoire JM; Vispé S; Schambel P; Ausseil F; Sautel F; Arimondo PB; Cantagrel F
ChemMedChem; 2014 Mar; 9(3):590-601. PubMed ID: 24678024
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β.
Sharma V; Verma V; Lal N; Yadav SK; Sarkar S; Mandalapu D; Porwal K; Rawat T; Maikhuri JP; Rajender S; Sharma VL; Gupta G
Mol Carcinog; 2016 Nov; 55(11):1843-1857. PubMed ID: 26599461
[TBL] [Abstract][Full Text] [Related]
5. A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.
Manara MC; Valente S; Cristalli C; Nicoletti G; Landuzzi L; Zwergel C; Mazzone R; Stazi G; Arimondo PB; Pasello M; Guerzoni C; Picci P; Nanni P; Lollini PL; Mai A; Scotlandi K
Mol Cancer Ther; 2018 Sep; 17(9):1881-1892. PubMed ID: 29959201
[TBL] [Abstract][Full Text] [Related]
6. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
[TBL] [Abstract][Full Text] [Related]
7. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Billam M; Sobolewski MD; Davidson NE
Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
[TBL] [Abstract][Full Text] [Related]
8. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.
Chiam K; Centenera MM; Butler LM; Tilley WD; Bianco-Miotto T
PLoS One; 2011; 6(9):e25634. PubMed ID: 21980513
[TBL] [Abstract][Full Text] [Related]
9. Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation.
Zwergel C; Fioravanti R; Stazi G; Sarno F; Battistelli C; Romanelli A; Nebbioso A; Mendes E; Paulo A; Strippoli R; Tripodi M; Pechalrieu D; Arimondo PB; De Luca T; Del Bufalo D; Trisciuoglio D; Altucci L; Valente S; Mai A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32075099
[TBL] [Abstract][Full Text] [Related]
10. The Epigenetic Modifier 5-Aza-2-deoxycytidine Triggers the Expression of
Dudzik P; Trojan SE; Ostrowska B; Zemanek G; Dulińska-Litewka J; Laidler P; Kocemba-Pilarczyk KA
Anticancer Res; 2019 May; 39(5):2395-2403. PubMed ID: 31092432
[TBL] [Abstract][Full Text] [Related]
11. New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors.
Gros C; Fleury L; Nahoum V; Faux C; Valente S; Labella D; Cantagrel F; Rilova E; Bouhlel MA; David-Cordonnier MH; Dufau I; Ausseil F; Mai A; Mourey L; Lacroix L; Arimondo PB
J Biol Chem; 2015 Mar; 290(10):6293-302. PubMed ID: 25525263
[TBL] [Abstract][Full Text] [Related]
12. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
[TBL] [Abstract][Full Text] [Related]
13. Low-dose DNA demethylating therapy induces reprogramming of diverse cancer-related pathways at the single-cell level.
Takeshima H; Yoda Y; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Clin Epigenetics; 2020 Sep; 12(1):142. PubMed ID: 32958049
[TBL] [Abstract][Full Text] [Related]
14. Identification and optimization of hydrazone-gallate derivatives as specific inhibitors of DNA methyltransferase 3A.
Erdmann A; Menon Y; Gros C; Masson V; Aussagues Y; Ausseil F; Novosad N; Schambel P; Baltas M; Arimondo PB
Future Med Chem; 2016; 8(4):373-80. PubMed ID: 26976348
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells.
Graça I; Sousa EJ; Baptista T; Almeida M; Ramalho-Carvalho J; Palmeira C; Henrique R; Jerónimo C
Curr Pharm Des; 2014; 20(11):1803-11. PubMed ID: 23888969
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
Kala R; Shah HN; Martin SL; Tollefsbol TO
BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
Lin J; Haffner MC; Zhang Y; Lee BH; Brennen WN; Britton J; Kachhap SK; Shim JS; Liu JO; Nelson WG; Yegnasubramanian S; Carducci MA
Prostate; 2011 Mar; 71(4):333-43. PubMed ID: 20809552
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel 3-halo-3-nitroflavanones and their activities as DNA methyltransferase inhibitors in cancer cells.
Pechalrieu D; Dauzonne D; Arimondo PB; Lopez M
Eur J Med Chem; 2020 Jan; 186():111829. PubMed ID: 31757526
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.
Gao XZ; Zhao WG; Wang GN; Cui MY; Zhang YR; Li WC
Mol Med Rep; 2016 Feb; 13(2):1269-74. PubMed ID: 26648013
[TBL] [Abstract][Full Text] [Related]
20. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
